18 and older, female only, with Fallopian Tube Cancer or Peritoneum Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Pathologic Objective Response Rate (pORR) in Participants Receiving Protocol TherapyPrimary· Up to 48 months
The pORR will be calculated as the percentage of participants with pathologic complete response (pCR) and pathologic partial response (pPR) overall as best response. For this protocol, pathologic complete response (pCR) will be defined as no residual macroscopic or (viable) microscopic disease. Pathologic partial response (pPR) will be defined as the presence of residual (viable) microscopic tumor, and the size of the largest focus will be provided for possible outcome correlation.
Group
Value
95% CI
Pembrolizumab, Paclitaxel + Carboplatin
60
38.7 – 78.9
Progression-Free Survival (PFS)Secondary· Up to 48 months
Progression-Free Survival (PFS) is measured from date of start of treatment to the earliest occurrence of any of the following events: documented disease progression or death from any cause. Patients who are alive and progression-free will be censored at the date of last documented progression-free status which is the date of last tumor assessment according to RECIST v1.1.
Group
Value
95% CI
Pembrolizumab, Paclitaxel + Carboplatin
22.5
11.9 – NA
Number of Participants Experiencing Treatment-related ToxicitySecondary· Up to 48 Months
Safety and tolerability of the intervention will be reported as the number of participants experiencing treatment-related toxicity including serious adverse events (SAEs) and adverse events (AEs), as assessed by treating physician. Toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0, per physician discretion.
All Treatment-related SAEs
Group
Value
95% CI
Pembrolizumab, Paclitaxel + Carboplatin
3
Grade 3 or higher treatment-related SAEs
Group
Value
95% CI
Pembrolizumab, Paclitaxel + Carboplatin
1
All Treatment-related AEs (excluding SAEs)
Group
Value
95% CI
Pembrolizumab, Paclitaxel + Carboplatin
23
Grade 3 or higher treatment-related AEs (excluding SAEs)
Group
Value
95% CI
Pembrolizumab, Paclitaxel + Carboplatin
10
Adverse events — posted to ClinicalTrials.gov
Time frame: 48 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The investigators hypothesize that tumor cell killing by cytotoxic chemotherapy exposes the immune system to high levels of tumor antigens.The combination of Paclitaxel/Carboplatin and Pembrolizumab may result in deeper and more durable responses compared with standard chemotherapy alone.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem
· Phase 2, PHASE3
· not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand
· Phase 2
· not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan
· Phase 1, PHASE2
· recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
· Phase 1
· not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
· Phase 3
· not yet recruiting
Other recruiting trials for Fallopian Tube Cancer
Currently open trials in the same condition.
NCT07402915 — Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian
· Phase 1
· recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo
· Phase 3
· recruiting
NCT06787612 — Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
· Phase 2
· recruiting
NCT07023484 — Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
· Phase 2
· recruiting
NCT07460180 — The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cy
· Phase 1, PHASE2
· recruiting
Other University of Miami trials
Trials by the same sponsor.
NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI)
· NA
· not yet recruiting
NCT06077071 — MRIdian "RADAR" Trial
· NA
· not yet recruiting
NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
· Phase 3
· not yet recruiting
NCT07322289 — Antibiotic-coated Braided Suture Study
· NA
· not yet recruiting
NCT07469592 — eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Miami
Last refreshed: 7 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02834975.